Gwathmey Preclinical Testing Services, Inc. offers a unique suite of services in preclinical evaluation of potential drug candidates for cardiac safety – its specialized Cardionomics™ services.
The topic of the cardiac safety of new drugs is one that has long been a priority for pharmaceutical companies, and which has taken on additional urgency in recent years. Gwathmey, inc. has developed its Cardionomics™ team to help answer a growing need among drug makers for skilled, specialized, and immediately available cardiac safety screening expertise and technologies. Gwathmey Preclinical’s role is to help design and execute stronger preclinical studies to help eliminate the risk of cardiac safety issues in drugs before they hit the pipeline or clinical trials.
In support of the new services, Gwathmey Preclinical Testing Services, Inc. has assembled a world-class physician and researcher advisory board for its Cardionomics™ Services. All Cardionomics™ Advisory Board members are highly-sought after scientists with vast industry experience and unquestioned academic excellence, as well as specialized expertise in running clinical trials.
Features of Gwathmey Preclinical’s Cardionomics™ Services include:
Cardionomics™ Advisory Board
Our Cardionomics™ Advisory Board Members include:
Section Head, Clinical Cardiology
Cleveland Clinic
Electrophysiology and Professor of Medicine
Beth Israel Deaconess Medical Center
Professor, Medicine / Cardiology Professor
Mt. Sinai Department of Gene and Cell Medicine
Chief, Cardiology Division
VA Hospital
Professor of Pharmacology and Pediatrics
Columbia University College of Physicians and Surgeons
Chair, Cell Biology and Molecular Medicine, Professor
University of Medicine and Dentistry of New Jersey